News
FDA Officials Detail Plan to Limit COVID Shots
The FDA also gave full approval to the Novavax COVID vaccine (Nuvaxovid) using this approach, approving it for those ages 65 and up, along with people ages 12 and up who have at least one underlying condition that puts them at risk of severe disease.
The US Food and Drug Administration has fully approved a new COVID vaccine option specifically targeting high-risk individuals, including seniors. The protein-based Nuvaxovid vaccine, produced by ...
The most commonly reported adverse events with the AZD1222 COVID-19 vaccine are headache and fatigue, a large-scale active ...
Agency leaders said there was evidence to justify approval only for older people and those with medical conditions. Many ...
Under a new policy announced Tuesday by the Trump administration, only people age 65 and older and children or young adults ...
In recent interviews, Health and Human Services Secretary Robert F. Kennedy Jr. has minimized the risk COVID-19 poses to kids ...
Federal officials unveiled a rigorous regulatory approach to future COVID vaccines that could make it harder for many people ...
U.S. regulators will no longer approve COVID booster shots for healthy adults and children without new studies, adding a ...
Live Science on MSN1d
2-in-1 COVID-flu vaccine looks promising in trial — but experts say approval may be delayedLate-stage trial data suggest that a new COVID-flu vaccine offers good protection against both infections, but experts expect ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback